[go: up one dir, main page]

DE60023476D1 - Kombination von doctaxel und rhumab her2 zür krebsbehandlung - Google Patents

Kombination von doctaxel und rhumab her2 zür krebsbehandlung

Info

Publication number
DE60023476D1
DE60023476D1 DE60023476T DE60023476T DE60023476D1 DE 60023476 D1 DE60023476 D1 DE 60023476D1 DE 60023476 T DE60023476 T DE 60023476T DE 60023476 T DE60023476 T DE 60023476T DE 60023476 D1 DE60023476 D1 DE 60023476D1
Authority
DE
Germany
Prior art keywords
rhumab her2
doctaxel
combination
cancer treatment
docetaxel
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60023476T
Other languages
English (en)
Other versions
DE60023476T2 (de
Inventor
Charles Le Vogel
E Bellet
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Aventis Pharma SA
Original Assignee
Aventis Pharma SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22435924&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE60023476(D1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Aventis Pharma SA filed Critical Aventis Pharma SA
Application granted granted Critical
Publication of DE60023476D1 publication Critical patent/DE60023476D1/de
Publication of DE60023476T2 publication Critical patent/DE60023476T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Drying Of Gases (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Plant Substances (AREA)
DE60023476T 1999-04-09 2000-04-07 Kombination von doctaxel und rhumab her2 zur krebsbehandlung Expired - Lifetime DE60023476T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US12856499P 1999-04-09 1999-04-09
US128564P 1999-04-09
PCT/US2000/009247 WO2000061185A1 (en) 1999-04-09 2000-04-07 Docetaxel in combination with rhumab her2 for the treatment of cancers

Publications (2)

Publication Number Publication Date
DE60023476D1 true DE60023476D1 (de) 2005-12-01
DE60023476T2 DE60023476T2 (de) 2006-07-06

Family

ID=22435924

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60023476T Expired - Lifetime DE60023476T2 (de) 1999-04-09 2000-04-07 Kombination von doctaxel und rhumab her2 zur krebsbehandlung

Country Status (22)

Country Link
US (1) US6333348B1 (de)
EP (1) EP1169059B1 (de)
JP (2) JP2003512298A (de)
KR (1) KR100695383B1 (de)
CN (1) CN1191859C (de)
AT (1) ATE307608T1 (de)
AU (1) AU777661B2 (de)
BR (1) BR0009647A (de)
CA (1) CA2368369C (de)
CZ (1) CZ296373B6 (de)
DE (1) DE60023476T2 (de)
DK (1) DK1169059T3 (de)
EA (1) EA006097B1 (de)
ES (1) ES2248070T3 (de)
HK (2) HK1046093B (de)
HU (1) HU226672B1 (de)
MX (1) MXPA01010138A (de)
NO (1) NO332619B1 (de)
NZ (1) NZ515337A (de)
TR (1) TR200102845T2 (de)
WO (1) WO2000061185A1 (de)
ZA (1) ZA200107771B (de)

Families Citing this family (65)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA9811162B (en) 1997-12-12 2000-06-07 Genentech Inc Treatment with anti-ERBB2 antibodies.
EP1098665B9 (de) * 1998-07-13 2003-08-13 The Board Of Regents, The University Of Texas System Krebsbehandlung mit aminophospholipide bindenden, therapeutischen konjugaten
US6406693B1 (en) * 1998-07-13 2002-06-18 Board Of Regents, The University Of Texas System Cancer treatment methods using antibodies to aminophospholipids
EP1096955B9 (de) * 1998-07-13 2006-07-05 Board of Regents, The University of Texas System Verwendung von antikörper gegen aminophospholipide zur krebsbehandlung
US6818213B1 (en) * 1998-07-13 2004-11-16 Board Of Regents, The University Of Texas System Cancer treatment compositions comprising therapeutic conjugates that bind to aminophospholipids
US6333348B1 (en) * 1999-04-09 2001-12-25 Aventis Pharma S.A. Use of docetaxel for treating cancers
KR100754049B1 (ko) * 1999-06-25 2007-08-31 제넨테크, 인크. 전립선암을 치료하기 위한 약제 제조에 사용되는 항-ErbB2 항체 및 조성물
US6949245B1 (en) 1999-06-25 2005-09-27 Genentech, Inc. Humanized anti-ErbB2 antibodies and treatment with anti-ErbB2 antibodies
US20040013667A1 (en) * 1999-06-25 2004-01-22 Genentech, Inc. Treatment with anti-ErbB2 antibodies
US7041292B1 (en) 1999-06-25 2006-05-09 Genentech, Inc. Treating prostate cancer with anti-ErbB2 antibodies
GB9917012D0 (en) * 1999-07-20 1999-09-22 Pharmacia & Upjohn Spa Combined preparations comprising antitumor agents
KR20090126330A (ko) 1999-08-27 2009-12-08 제넨테크, 인크. 항-ＥｒｂＢ2 항체 투여 치료 방법
KR20080038458A (ko) 2000-05-19 2008-05-06 제넨테크, 인크. ＥｒｂＢ 길항제에 의한 암 치료요법에 대한 효과적인반응의 가능성을 개선시키기 위한 유전자 검출 분석
AU2002232413A1 (en) * 2000-11-21 2002-06-03 Cell Pathways, Inc. Method for treating neoplasia by administering an anti-her2 antibody and a cgmp-specific phosphodiesterase inhibitor
ES2236481T3 (es) * 2001-01-16 2005-07-16 Glaxo Group Limited Combinacion farmaceutica que contiene una 4-quinazolinamina y paclitaxel, carboplatino o vinorelbina para el tratamiento de cancer.
CN104083365A (zh) * 2001-02-19 2014-10-08 诺华股份有限公司 癌症的治疗
WO2002087629A1 (en) * 2001-04-26 2002-11-07 Analogic Corporation Ct scanner for imaging a preselected portion of a patient
US7452539B2 (en) * 2001-12-19 2008-11-18 Genentech, Inc. Stabilizing polypeptides which have been exposed to urea
GB0200657D0 (en) * 2002-01-12 2002-02-27 Antisoma Plc Cancer treatment
US7615223B2 (en) * 2002-07-15 2009-11-10 Board Of Regents, The University Of Texas System Selected immunoconjugates for binding to aminophospholipids
US7572448B2 (en) * 2002-07-15 2009-08-11 Board Of Regents, The University Of Texas System Combined cancer treatment methods using selected antibodies to aminophospholipids
US7678386B2 (en) * 2002-07-15 2010-03-16 Board Of Regents The University Of Texas Liposomes coated with selected antibodies that bind to aminophospholipids
US7247303B2 (en) * 2002-07-15 2007-07-24 Board Of Regents, The University Of Texas System Selected antibody CDRs for binding to aminophospholipids
US7625563B2 (en) * 2002-07-15 2009-12-01 Board Of Regents, The University Of Texas System Cancer treatment methods using selected immunoconjugates for binding to aminophospholipids
US7714109B2 (en) * 2002-07-15 2010-05-11 Board Of Regents, The University Of Texas System Combinations and kits for cancer treatment using selected antibodies to aminophospholipids
US7622118B2 (en) * 2002-07-15 2009-11-24 Board Of Regents, The University Of Texas System Cancer treatment methods using selected antibodies to aminophospholipids
CA2491310C (en) * 2002-07-15 2015-10-06 Board Of Regents, The University Of Texas System Compositions comprising cell-impermeant duramycin derivatives
EP1572972A4 (de) * 2002-11-21 2007-11-21 Genentech Inc Therapie nichtmaligner krankheiten oder störungen mit anti-erbb2-antikörpern
US7989490B2 (en) * 2004-06-02 2011-08-02 Cordis Corporation Injectable formulations of taxanes for cad treatment
PL1846030T3 (pl) 2005-01-21 2019-05-31 Genentech Inc Ustalone dawkowanie przeciwciał her
ZA200706247B (en) * 2005-02-09 2008-11-26 Genentech Inc Inhibiting HER2 shedding with matrix metalloprotease antagonists
EP3195879A1 (de) 2005-02-23 2017-07-26 Genentech, Inc. Ausdehnungszeit einer krankheitsprogression oder -überlebens bei krebspatienten
JP2006316040A (ja) 2005-05-13 2006-11-24 Genentech Inc Ｈｅｒｃｅｐｔｉｎ（登録商標）補助療法
WO2007038792A2 (en) * 2005-09-28 2007-04-05 H. Lee Moffitt Cancer Center Individualized cancer treatments
EP1913958B1 (de) * 2006-08-03 2009-12-23 Sanofi-Aventis Antitumorale Zusammensetzungen enthaltend Acetylcyclopropyl Docetaxel und Trastuzumab
FR2904782B1 (fr) * 2006-08-11 2008-10-31 Delta Proteomics Soc Par Actio Co-colloides supramoleculaires obtenus a l'aide de systemes macrocycliques polyanioniques
WO2008109440A2 (en) 2007-03-02 2008-09-12 Genentech, Inc. Predicting response to a her dimerisation inhibitor based on low her3 expression
US9551033B2 (en) 2007-06-08 2017-01-24 Genentech, Inc. Gene expression markers of tumor resistance to HER2 inhibitor treatment
EP2592156B1 (de) 2007-06-08 2016-04-20 Genentech, Inc. Genexpressionsmarker für Tumorresistenz gegen Behandlung mit HER2-Inhibitor
EP2133433A1 (de) * 2008-06-09 2009-12-16 Centre Georges François Leclerc Verfahren zur Vorhersage der Reaktion auf eine Behandlung mit einem Antikörper gegen HER2
BRPI0812682A2 (pt) 2008-06-16 2010-06-22 Genentech Inc tratamento de cáncer de mama metastático
EP2358199A2 (de) * 2008-11-02 2011-08-24 Optimata Ltd. Verbesserung der krebs-therapie durch docetaxel und des granulozyt-colony stimulierungsfaktor (g-csf)
MD35Z (ro) * 2008-12-02 2010-01-31 Василе ЖОВМИР Metodă de apreciere a riscului dezvoltării carcinomului neinvaziv in situ al glandei mamare
MD36Z (ro) * 2008-12-02 2010-01-31 Василе ЖОВМИР Metodă de tratament diferenţiat al carcinomului ductal in situ neinvaziv al glandei mamare
MD24Z (ro) * 2008-12-02 2010-01-31 Василе ЖОВМИР Metodă de tratament diferenţiat al carcinomului neinvaziv al glandei mamare
MD23Z (ro) * 2008-12-02 2010-01-31 Василе ЖОВМИР Metodă de tratament diferenţiat al carcinomului lobular in situ neinvaziv al glandei mamare
AR075896A1 (es) 2009-03-20 2011-05-04 Genentech Inc Anticuerpos anti-her (factor de crecimiento epidermico)
WO2010136569A1 (en) 2009-05-29 2010-12-02 F. Hoffmann-La Roche Ag Modulators for her2 signaling in her2 expressing patients with gastric cancer
CA2784211C (en) 2010-02-18 2019-12-24 Genentech, Inc. Neuregulin antagonists and use thereof in treating cancer
WO2011139172A1 (en) 2010-05-06 2011-11-10 Goran Milosavljevic Diterpene compounds with antineoplastic activities and pharmaceutical compositions comprising same
WO2011146568A1 (en) 2010-05-19 2011-11-24 Genentech, Inc. Predicting response to a her inhibitor
WO2012069466A1 (en) 2010-11-24 2012-05-31 Novartis Ag Multispecific molecules
SG191153A1 (en) 2010-12-23 2013-07-31 Hoffmann La Roche Polypeptide-polynucleotide-complex and its use in targeted effector moiety delivery
CN103890007A (zh) 2011-08-17 2014-06-25 霍夫曼-拉罗奇有限公司 神经调节蛋白抗体及其用途
MX357759B (es) * 2011-09-01 2018-07-24 Vascular Biogenics Ltd Formulaciones y formas de dosificacion de fosfolipidos oxidados.
CN102321175B (zh) * 2011-09-21 2013-08-07 天津胜发生物技术有限公司 针对乳腺癌Her2/new的纳米抗体或多肽
US9327023B2 (en) 2011-10-25 2016-05-03 The Regents Of The University Of Michigan HER2 targeting agent treatment in non-HER2-amplified cancers having HER2 expressing cancer stem cells
WO2013081645A2 (en) 2011-11-30 2013-06-06 Genentech, Inc. Erbb3 mutations in cancer
EP2788500A1 (de) 2011-12-09 2014-10-15 F.Hoffmann-La Roche Ag Identifizierung von non-respondern auf her2-inhibitoren
JP2015514710A (ja) 2012-03-27 2015-05-21 ジェネンテック， インコーポレイテッド Ｈｅｒ３阻害剤に関する診断及び治療
US9308235B2 (en) 2012-05-09 2016-04-12 Spectrum Pharmaceuticals, Inc. Treatment of primary and metastatic carcinoma
CA2889298C (en) 2012-11-30 2024-01-02 Anton Belousov Identification of patients in need of pd-l1 inhibitor cotherapy
CN103102414B (zh) * 2013-02-04 2014-08-27 无锡傲锐东源生物科技有限公司 抗her2蛋白单克隆抗体及其用途
EP3454863A1 (de) 2016-05-10 2019-03-20 INSERM (Institut National de la Santé et de la Recherche Médicale) Kombinationstherapien zur behandlung von krebs
CN109966499A (zh) * 2019-04-25 2019-07-05 苏州大学 协同增效的抗乳腺癌转移药物组合物及其用途

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6214388B1 (en) 1994-11-09 2001-04-10 The Regents Of The University Of California Immunoliposomes that optimize internalization into target cells
ZA9811162B (en) 1997-12-12 2000-06-07 Genentech Inc Treatment with anti-ERBB2 antibodies.
US6333348B1 (en) * 1999-04-09 2001-12-25 Aventis Pharma S.A. Use of docetaxel for treating cancers

Also Published As

Publication number Publication date
DE60023476T2 (de) 2006-07-06
HK1043313A1 (zh) 2002-09-13
JP2003512298A (ja) 2003-04-02
EP1169059A1 (de) 2002-01-09
DK1169059T3 (da) 2006-02-27
CZ20013614A3 (cs) 2002-07-17
US6333348B1 (en) 2001-12-25
HUP0201459A2 (en) 2002-09-28
CA2368369C (en) 2014-03-25
CZ296373B6 (cs) 2006-03-15
CN1191859C (zh) 2005-03-09
WO2000061185A1 (en) 2000-10-19
MXPA01010138A (es) 2003-07-14
ATE307608T1 (de) 2005-11-15
CA2368369A1 (en) 2000-10-19
KR100695383B1 (ko) 2007-03-15
JP2012136535A (ja) 2012-07-19
EA200101064A1 (ru) 2002-04-25
HK1046093B (zh) 2005-10-28
HK1046093A1 (en) 2002-12-27
TR200102845T2 (tr) 2002-01-21
HU226672B1 (en) 2009-06-29
AU777661B2 (en) 2004-10-28
HUP0201459A3 (en) 2003-04-28
ES2248070T3 (es) 2006-03-16
KR20020007358A (ko) 2002-01-26
BR0009647A (pt) 2002-01-08
NO20014842L (no) 2001-10-04
CN1350464A (zh) 2002-05-22
EP1169059B1 (de) 2005-10-26
EA006097B1 (ru) 2005-08-25
ZA200107771B (en) 2002-09-20
AU4332700A (en) 2000-11-14
NO20014842D0 (no) 2001-10-04
NZ515337A (en) 2003-10-31
NO332619B1 (no) 2012-11-19

Similar Documents

Publication Publication Date Title
DE60023476D1 (de) Kombination von doctaxel und rhumab her2 zür krebsbehandlung
TW200518752A (en) Combinations of drugs for the treatment of neoplasms
WO2004062604A3 (en) Treatment of cancer with 2-deoxyglucose
MXPA03010121A (es) Terapia de combinacion que utiliza anticuerpos anti-receptor de factor de crecimiento epidermico y agentes anti-hormonales.
BR0115109A (pt) Agentes terapêuticos e métodos de uso dos mesmos para a modulação da angiogênese
YU13603A (sh) Postupci tretiranja poremećaja povenzanih sa bcl-2 primenom bcl-2 antisens oligomera
DK1289517T3 (da) Farmaceutiske sammensætninger indeholdende cannabidiolderivater
WO2004006842A3 (en) Combinations of drugs for the treatment of neoplasms
MX9302038A (es) Metodo para el tratamiento del cancer por una terapia conjunta con derivados de 2-halometilideno y un agente antineoplasico especifico de fase m o fase s.
BR9813318A (pt) Processo de tratamento de tumores e degeneração macular em paciente humano ou veterinário, composição farmacêutica para tratamento de tumores e degeneração macular em um paciente humano ou veterinário
UA32457C2 (uk) Лікарський засіб (варіанти) і спосіб медикаментозного впливу на організм
DE602004016376D1 (de) Kombination von et-743 mit 5-fluorouracil pro-drugs zur behandlung von krebs
DE60222383D1 (de) Medikament zur verabreichung von amifostin und verwandten wirkstoffen
MXPA04001912A (es) Aminobenzofenonas novedosas.
WO2004056971A3 (en) Methods of treatment of a bcl-2 disorder using bcl-2 antisense oligomers
BRPI0404050A (pt) Uso de um composto ou de um seu sal ou éster farmaceuticamente aceitável, formulação farmacêutica, formulação acondicionada, composto, e, método para prevenir e/ou tratar hiperplasia benigna da próstata em pacientes em necessidade de tal prevenção ou tratamento
ATE345805T1 (de) Calciumtrifluoracetat mit zytotoxischer wirkung
WO2002076393A3 (en) Antiagionecic, antitumor, chemopreventative agents
AU2002319223A1 (en) Medicament for treating tumours and their metastases using a binding molecule against bone-sialoprotein
RU2003124971A (ru) Способ лечения больных с невротическими и соматоформными расстройствами
DK1150981T3 (da) Terapeutisk necleosidforbindelse
FI20010233A0 (fi) Menetelmä sydämen vajaatoiminnan hoitoon
DE60125377D1 (de) Behandlung von hepatitis c mit thymosin, interferon und ribavirin
MXPA05008879A (es) Una terapia combinada que comprende un derivado de indolopirrolocarbazol y otro agente antitumoral.
DE60121449D1 (de) Behandlung von hepatitis c mit thymosin und pegyliertem interferon

Legal Events

Date Code Title Description
8328 Change in the person/name/address of the agent

Representative=s name: PFENNING MEINIG & PARTNER GBR, 80339 MUENCHEN

8364 No opposition during term of opposition
8328 Change in the person/name/address of the agent

Representative=s name: MAIWALD PATENTANWALTSGESELLSCHAFT MBH, 80335 MUENC

8310 Action for declaration of annulment
8328 Change in the person/name/address of the agent

Representative=s name: BIRD & BIRD LLP, 80333 MUENCHEN